SP
BMRN icon

Sarasin & Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sarasin & Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-105,681
Closed -$7.43M – 134
2013
Q4 		$7.43M Hold
105,681
– – 0.1% 68
2013
Q3 		$7.63M Hold
105,681
– – 0.12% 61
2013
Q2 		$5.89M Buy
+105,681
New +$6.59M 0.08% 80

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sarasin & Partners's BMRN Position: Q1 2014 in Review

Sarasin & Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2014, closing a stake of 105,681 shares — an estimated $7.43M sold.

Sarasin & Partners first reported a position in BMRN in Q2 2013 and held it in 3 quarters. The position peaked at $7.63M in Q3 2013. 313 funds tracked by Wall St. Rank hold BMRN as of Q1 2014.

  • Sarasin & Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Sarasin & Partners sold 105,681 BioMarin Pharmaceuticals shares in Q1 2014, an estimated $7.43M.
  • Sarasin & Partners first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Sarasin & Partners's BioMarin Pharmaceuticals position peaked at $7.63M in Q3 2013.
  • 313 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2014.

Based on Sarasin & Partners's 13F filing for Q1 2014, filed 9 Apr 2014.